148 - References

References

Schizophrenia and related psychoses CHAPTER 1 References

1. Pillinger T, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-­analysis. Lancet Psychiatry 2020; 7:64–77.
2. Bak M, et al. Almost all antipsychotics result in weight gain: a meta-­analysis. PLoS One 2014; 9:e94112.
3. Stamoula E, et al. Weight gain, gender, and antipsychotics: a disproportionality analysis of the FDA Adverse Event Reporting System database (FAERS). Expert Opin Drug Saf 2024; 23:239–245.
4. Marder SR, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334–1349.
5. Cooper SJ, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol 2016; 30:717–748.
6. Galletly C, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016; 50:410–472.
7. American Diabetes Association, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596–601.
8. Vandenberghe F, et al. Importance of early weight changes to predict long-­term weight gain during psychotropic drug treatment. J Clin Psychiatry 2015; 76:e1417–1423.
9. Lipkovich I, et al. Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry 2008; 8:78.
10. Fitzgerald I, et al. Predicting antipsychotic-­induced weight gain in first episode psychosis: a field-­wide systematic review and meta-­analysis of non-­genetic prognostic factors. Eur Psychiatry 2023; 66:e42.
11. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults. Quality standard [QS80]. 2015 (last accessed February 2024); https://www.nice.org.uk/guidance/qs80.
12. Mitchell AJ, et al. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-­analysis of screening practices. Psychol Med 2012; 42:125–147.
13. Barnes TR, et al. Screening for the metabolic side effects of antipsychotic medication: findings of a 6-­year quality improvement programme in the UK. BMJ Open 2015; 5:e007633.
14. Crawford MJ, et al. Assessment and treatment of physical health problems among people with schizophrenia: national cross-­sectional study. Br J Psychiatry 2014; 205:473–477.
15. Hammoudeh S, et al. Risk factors of metabolic syndrome among patients receiving antipsychotics: a retrospective study. Community Ment Health J 2020; 56:760–770.
16. Ward T, et al. Who is responsible for metabolic screening for mental health clients taking antipsychotic medications? Int J Ment Health Nurs 2018; 27:196–203.
17. Bruins J, et al. The effects of lifestyle interventions on (long-­term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: a meta-­analysis. PLoS One 2014; 9:e112276.
18. Mizuno Y, et al. Pharmacological strategies to counteract antipsychotic-­induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-­analysis. Schizophr Bull 2014; 40:1385–1403.
19. Stroup TS, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011; 168:947–956.
20. Mukundan A, et al. Antipsychotic switching for people with schizophrenia who have neuroleptic-­induced weight or metabolic problems. Cochrane Database Syst Rev 2010; (12):CD006629.
21. Montes JM, et al. Improvement in antipsychotic-­related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:383–388.
22. Wu H, et  al. Antipsychotic-­induced weight gain: dose-­response meta-­analysis of randomized controlled trials. Schizophr Bull 2022; 48:643–654.
23. Akinola PS, et al. Antipsychotic-­induced metabolic syndrome: a review. Metab Syndr Relat Disord 2023; 21:294–305.
24. Galling B, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-­analysis and meta-­regression analysis. World Psychiatry 2017; 16:77–89.
25. de Kuijper G, et al. Effects of controlled discontinuation of long-­term used antipsychotics on weight and metabolic parameters in individuals with intellectual disability. J Clin Psychopharmacol 2013; 33:520–524.
26. Chen EY, et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ 2010; 341:c4024.
27. Speyer H, et al. Reversibility of antipsychotic-­induced weight gain: a systematic review and meta-­analysis. Front Endocrinol (Lausanne) 2021; 12:577919.
28. Werneke U, et al. Behavioural management of antipsychotic-­induced weight gain: a review. Acta Psychiatr Scand 2003; 108:252–259.
29. Caemmerer J, et al. Acute and maintenance effects of non-­pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-­analytic comparison of randomized controlled trials. Schizophr Res 2012; 140:159–168.
30. Rice J, et al. Integrative management of metabolic syndrome in youth prescribed second-­generation antipsychotics. Med Sci (Basel) 2020; 8:34.
31. Vancampfort D, et al. The impact of pharmacological and non-­pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-­review of meta-­analyses of randomized controlled trials. World Psychiatry 2019; 18:53–66.
32. Naslund JA, et al. Lifestyle interventions for weight loss among overweight and obese adults with serious mental illness: a systematic review and meta-­analysis. Gen Hosp Psychiatry 2017; 47:83–102.

148 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 33. Mohanty K, et al. Effectiveness of lifestyle intervention on prevention/management of antipsychotic-­induced weight gain among persons with severe mental illness: a systematic review and meta-­analysis. J Health Psychol 2024; 29:690–706. 34. Lee K, et al. Antipsychotic-­induced weight gain: exploring the role of psychiatrists in managing patients’ physical health –­ challenges, current options and direction for future care. BJPsych Bull 2024; 48:24–29. 35. Manu P, et  al. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand 2015; 132:97–108. 36. Kucukgoncu S, et al. Alpha-­lipoic acid (ALA) as a supplementation for weight loss: results from a meta-­analysis of randomized controlled trials. Obes Rev 2017; 18:594–601. 37. Kim E, et al. A preliminary investigation of alpha-­lipoic acid treatment of antipsychotic drug-­induced weight gain in patients with schizophrenia. J Clin Psychopharmacol 2008; 28:138–146. 38. Ratliff JC, et al. An open-­label pilot trial of alpha-­lipoic acid for weight loss in patients with schizophrenia without diabetes. Clin Schizophr Relat Psychoses 2015; 8:196–200. 39. Praharaj SK, et al. Amantadine for olanzapine-­induced weight gain: a systematic review and meta-­analysis of randomized placebo-­controlled trials. Ther Adv Psychopharmacol 2012; 2:151–156. 40. Zheng W, et  al. Amantadine for antipsychotic-­related weight gain: meta-­analysis of randomized placebo-­controlled trials. J Clin Psychopharmacol 2017; 37:341–346. 41. Zheng W, et  al. Efficacy and safety of adjunctive aripiprazole in schizophrenia: meta-­analysis of randomized controlled trials. J Clin Psychopharmacol 2016; 36:628–636. 42. Barak N, et al. A randomized, double-­blind, placebo-­controlled pilot study of betahistine to counteract olanzapine-­associated weight gain. J Clin Psychopharmacol 2016; 36:253–256. 43. Lian J, et al. Ameliorating antipsychotic-­induced weight gain by betahistine: mechanisms and clinical implications. Pharmacol Res 2016; 106:51–63. 44. Gadde KM, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res 2001; 9:544–551. 45. Jain AK, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002; 10:1049–1056. 46. Tsoi DT, et al. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 2013; 2:CD007253. 47. Weizman S, et al. A double-­blind, placebo-­controlled trial of bupropion add-­on to olanzapine or risperidone in overweight individuals with schizophrenia. J Clin Psychopharmacol 2021; 41:629–631. 48. Greig SL, et al. Naltrexone ER/bupropion ER: a review in obesity management. Drugs 2015; 75:1269–1280. 49. Hinze-­Selch D, et al. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology (Berl) 2000; 149:163–169. 50. Lu ML, et al. Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-­treated patients with schizophrenia: a 12-­week, randomized, double-­blind, placebo-­controlled study. Schizophr Res 2017; 193:126–133. 51. Lu ML, et  al. Adjunctive fluvoxamine inhibits clozapine-­related weight gain and metabolic disturbances. J Clin Psychiatry 2004; 65:766–771. 52. Larsen JR, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine-­ or olanzapine-­treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry 2017; 74:719–728. 53. Mayfield K, et  al. Glucagon-­like peptide-­1 agonists combating clozapine-­associated obesity and diabetes. J Psychopharmacol 2016; 30:227–236. 54. Lee K, et al. A systematic review of licensed weight-­loss medications in treating antipsychotic-­induced weight gain and obesity in schizophrenia and psychosis. Gen Hosp Psychiatry 2022; 78:58–67. 55. Siskind D, et al. Treatment of clozapine-­associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: a randomised controlled trial. Diabetes Obes Metab 2017; 20:1050–1055. 56. Ishoy PL, et al. Effect of GLP-­1 receptor agonist treatment on body weight in obese antipsychotic-­treated patients with schizophrenia: a randomized, placebo-­controlled trial. Diabetes Obes Metab 2017; 19:162–171. 57. Agahi M, et al. Effect of melatonin in reducing second-­generation antipsychotic metabolic effects: a double blind controlled clinical trial. Diabetes Metab Syndr 2017; 12:9–15. 58. Wang HR, et al. The role of melatonin and melatonin agonists in counteracting antipsychotic-­induced metabolic side effects: a systematic review. Int Clin Psychopharmacol 2016; 31:301–306. 59. Porfirio MC, et al. Can melatonin prevent or improve metabolic side effects during antipsychotic treatments? Neuropsychiatr Dis Treat 2017; 13:2167–2174. 60. Zheng W, et al. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-­analysis of randomized placebo-­controlled trials. J Clin Psychopharmacol 2015; 35:499–509. 61. Wang C, et al. Outcomes and safety of concomitant topiramate or metformin for antipsychotics-­induced obesity: a randomized-­controlled trial. Ann Gen Psychiatry 2020; 19:68. 62. Agarwal SM, et al. Pharmacological interventions for prevention of weight gain in people with schizophrenia. Cochrane Database Syst Rev 2022; 10:CD013337. 63. Stogios N, et al. Metformin for the prevention of clozapine-­induced weight gain: a retrospective naturalistic cohort study. Acta Psychiatr Scand 2022; 146:190–200. 64. Anagnostou E, et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial. JAMA Psychiatry 2016; 73:928–937.

Schizophrenia and related psychoses CHAPTER 1 65. Handen BL, et al. A randomized, placebo-­controlled trial of metformin for the treatment of overweight induced by antipsychotic medication in young people with autism spectrum disorder: open-­label extension. J Am Acad Child Adolesc Psychiatry 2017; 56:849-­856.e6. 66. Chapman LE, et al. Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes: a systematic review and meta-­analysis. Diabetes Metab 2016; 42:316–327. 67. Henderson DC, et al. Effects of modafinil on weight, glucose and lipid metabolism in clozapine-­treated patients with schizophrenia. Schizophr Res 2011; 130:53–56. 68. Roerig JL, et al. An exploration of the effect of modafinil on olanzapine associated weight gain in normal human subjects. Biol Psychiatry 2009; 65:607–613. 69. Taveira TH, et al. The effect of naltrexone on body fat mass in olanzapine-­treated schizophrenic or schizoaffective patients: a randomized double-­blind placebo-­controlled pilot study. J Psychopharmacol 2014; 28:395–400. 70. Tek C, et al. A randomized, double-­blind, placebo-­controlled pilot study of naltrexone to counteract antipsychotic-­associated weight gain: proof of concept. J Clin Psychopharmacol 2014; 34:608–612. 71. Sjostrom L, et al. Randomised placebo-­controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352:167–172. 72. Hilger E, et al. The effect of orlistat on plasma levels of psychotropic drugs in patients with long-­term psychopharmacotherapy. J Clin Psychopharmacol 2002; 22:68–70. 73. Pavlovic ZM. Orlistat in the treatment of clozapine-­induced hyperglycemia and weight gain. Eur Psychiatry 2005; 20:520. 74. Carpenter LL, et al. A case series describing orlistat use in patients on psychotropic medications. Med Health R I 2004; 87:375–377. 75. Joffe G, et al. Orlistat in clozapine-­ or olanzapine-­treated patients with overweight or obesity: a 16-­week randomized, double-­blind, placebo-­ controlled trial. J Clin Psychiatry 2008; 69:706–711. 76. Tchoukhine E, et al. Orlistat in clozapine-­ or olanzapine-­treated patients with overweight or obesity: a 16-­week open-­label extension phase and both phases of a randomized controlled trial. J Clin Psychiatry 2011; 72:326–330. 77. Chukhin E, et al. In a randomized placebo-­controlled add-­on study orlistat significantly reduced clozapine-­induced constipation. Int Clin Psychopharmacol 2013; 28:67–70. 78. Amrami-­Weizman A, et al. The effect of reboxetine co-­administration with olanzapine on metabolic and endocrine profile in schizophrenia patients. Psychopharmacology (Berl) 2013; 230:23–27. 79. Gao J, et al. Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder. Expert Rev Clin Pharmacol 2022; 15:1011–1016. 80. Laguado SA, et  al. Opioid antagonists to prevent olanzapine-­induced weight gain: a systematic review. Ment Health Clin 2022; 12:254–262. 81. Meyer JM, et al. Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patients. CNS Spectr 2023; 28:478–481. 82. Grywińska WB, et al. Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment. Postep Psychiatr Neurol 2023; 32:128–137. 83. Peng Z, et al. Effects of combined therapy of olanzapine and samidorphan on safety and metabolic parameters in schizophrenia patients: a meta-­analysis. Neuropsychiatr Dis Treat 2023; 19:2295–2308. 84. Kahn RS, et al. Olanzapine/samidorphan in young adults with schizophrenia, schizophreniform disorder, or bipolar I disorder who are early in their illness: results of the randomized, controlled ENLIGHTEN-­Early study. J Clin Psychiatry 2023; 84:22m14674. 85. Correll CU, et al. Reduction in multiple cardiometabolic risk factors with combined olanzapine/samidorphan compared with olanzapine: post hoc analyses from a 24-­week phase 3 study. Schizophr Bull 2023; 49:454–463. 86. Prasad F, et al. Semaglutide for the treatment of antipsychotic-­associated weight gain in patients not responding to metformin: a case series. Ther Adv Psychopharmacol 2023; 13:20451253231165169. 87. Stogios N, et al. Antipsychotic-­induced weight gain in severe mental illness: risk factors and special considerations. Curr Psychiatry Rep 2023; 25:707–721. 88. Correll CU, et al. Efficacy for psychopathology and body weight and safety of topiramate-­antipsychotic cotreatment in patients with schizophrenia spectrum disorders: results from a meta-­analysis of randomized controlled trials. J Clin Psychiatry 2016; 77:e746–e756. 89. Zheng W, et al. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-­analysis of randomized controlled trials. Acta Psychiatr Scand 2016; 134:385–398. 90. Buoli M, et  al. The use of zonisamide for the treatment of psychiatric disorders: a systematic review. Clin Neuropharmacol 2017; 40:85–92.